JLE

Hématologie

MENU

Maladie résiduelle dans le myélome Volume 25, supplément 2, Juin 2019

  • [1] Mailankody S., Korde N., Lesokhin A.M. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12:286-295. 5
  • [2] Swedin A., Lenhoff S., Olofsson T., Thuresson B., Westin J. Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma. Br J Haematol. 1998;103:1145-1151. 4
  • [3] Paiva B., van Dongen J.J.M., Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059-3068. 20
  • [4] Martinez-Lopez J., Lahuerta J.J., Pepin F. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123:3073-3079. 20
  • [5] Munshi N.C., Avet-Loiseau H., Rawstron A.C., Owen R.G., Child J.A., Thakurta A., Sherrington P., Samur M.K., Georgieva A., Anderson K.C., Gregory W.M. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myelom: a Meta-analysis. JAMA Oncol. 2017;3:28-35. 1
  • [6] Flores-Montero J., Sanoja-Flores L., Paiva B. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;10:2094-2102.
  • [7] Perrot A., Lauwers-Cances V., Corre J. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456-2464. 23